OA12781A

OA12781A - Thiazole and oxazole derivatives that modulate PPAR activity.

Info

Publication number: OA12781A
Application number: OA1200400233A
Authority: OA
Inventors: Xue-Min Cheng; Noe Ouano Erasga; Gary Frderick Filzen; Andrew George Geyer; Chitase Lee; Bharatu Kalidas Trivedi
Original assignee: Warner Lambert Co
Priority date: 2002-03-07
Filing date: 2003-03-03
Publication date: 2006-07-07
Also published as: JP2005524665A; HRP20040810A2; TW200400027A; GT200300053A; MA27182A1; CA2476580A1; PL372971A1; TNSN04167A1; EP1485091A1; BR0308221A; IL163768A0; ZA200406491B; ECSP045275A; WO2003074052A1; AR038883A1; PA8568701A1; UY27704A1; NO20044245L; CO5601013A2; IS7399A

Abstract

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

Description

01278 1

THIAZOLE AND OXAZOLE DERIVATIVES TI IAT MODULATE PPAR ACTIVITY FEELD OF THE INVENTION5

The présent invention relates to compounds and pharmaceuticalformulations that can be used to treat conditions mediated by nuclear hormonereceptors, more specifically, to compounds and pharmaceutical formulations thatmodulate PPAR activity. 10

B ACKGROUND OF THE INVENTION

Hypercholesterolemia, hyperlipidemia, and diabètes are well recognizedrisk factors in the onset of atherosclerosis and coronary heart disease. 15 Hypercholesterolemia and hyperlipidemia are characterized by excessively highleveîs of blood cholestérol and lipids. The blood cholestérol pool is generallydépendent on dietary uptake of cholestérol from the intestine and biosynthesis ofcholestérol throughout the body, especially the liver. The majority of cholestérolin plasma is carried on apolipoprotein B-containing lipoproteins, such as low- 20 density lipoproteins (LDL) and very-îow-density lipoproteins (VLDL). The riskof coronary artery disease in man increases when LDL and VLDL levels increase.Conversely, high levels of cholestérol carried in high-density lipoproteins (HDL)is protective against coronary artery disease (Am. J. Med., 1977; 62:707-714). · 25 The statins represent perhaps the most important class of lipid-lowering drugs. These compounds inhibit HMG-CoA reductase which is implicated in therate-limiting step in cellular cholestérol biosynthesis. Représentative statinsinclude atorvastatin, lovastatin, pravastatin, and simvastatin. The effectiveness ofthese compounds dépends on LDL receptor régulation. Other important 30 antilipidemia drugs include fibrates such as gemfibril and clofîbrate, bile acidséquestrants such as cholestyramine and colestipol, probucol, and nicotinic acidanalogs. 1 012781 Το date, a number of oral antidiabetic agents hâve been developed. Themost commonly used hypoglygemic drugs are the sulfonylureas. Sulfonylureasare generally used to stimulate insulin. The biguanide metformin is generallyused to improve insulin sensitivity and to decrease hepatic glucose output.Acarbose is used to lirait postprandial hyperglycemia. Thiazolidine 2,4 diones areused to enhance insulin action without increasing insulin sécrétion.

Peroxisome Proliferator Activation Receptors (PPAR) are implicated in anumber of biological pro'cesses and disease States including hypercholesterolemia,hyperlipidemia, and diabètes. PPARs are members of the nuclear receptorsuperfamily of transcription factors that includes steroid, thyroid, and vitamin Dreceptors. They play a rôle in controlling expression of proteins that regulate lipidmetabolism. Furthermore, the PPARs are activated by fatty acids and fatty acidmétabolites. There are three PPAR subtypes PPAR a, PPAR β (also referred to asPPAR δ), and PPAR γ. Each receptor shows a different pattem of tissueexpression, and différences in activation by structurally diverse compounds. PPAR γ, for instance, is expressed most abundantly in adipose tissue and at lowerlevels in skeletal muscle, heart, liver, intestine, kidney, vascular endothélial andsmooth muscle cells as well as macrophages. PPAR receptors are associated withrégulation of insulin sensitivity and blood glucose levels, macrophagedifférentiation, inflammatory response, and cell différentiation. Accordingly,PPARs hâve been associated with obesity, diabètes, carcinogenesis, hyperplasia,atherosclerosis, hyperlipidemia, and hypercholesterolemia.

In addition, PPARa agonists lower plasma triglycérides and LDLcholestérol and are therefore useful in treating hypertriglyceridemia,hyperlipidemia and obesity. PPAR γ is associated with the development of non-insulin-dependent diabètes mellitus (NEDDM), hypertension, coronary arterydisease, hyperlipidemia and certain malignancies. Finally, activation of PPAR βhas been demonstrated to increase HDL levels. (Leibowitz, WO97/28149, Aug.1997.) More recently, a PPAR β sélective agonist was reported to hâve shown adose-related increase in sérum HDL-C and decrease in LDL-C and VLDL-TG in 2 012787 insulin-resistant middle aged rhésus monkeys. (W. R. Oliver et al., PNAS, v. 98,pp. 5306-5311,2001)

Antilipidemic and antidiabetic agents are still considered to hâve non-5 uniform effectiveness. The effectivieness of antidiabetic and antilipidemic thérapies is limited, in part because of poor patient compliance due tounacceptable side effects. These side effects include diarrhea and gastrointestinaldiscomfort, and in the case of antidiabetics, edema, hypoglycemia andhepatoxicity. Furthermore, each type of drug does not work equally well in ail 10 patients.

For the reasons set forth above, there is a need for novel antilipidemic andantidiabetic agents that can be used alone or in combination. Furthermore,activation of PPARP alone or in combination with the simultaneous activation of 15 PPAR a and/or PPAR γ may be désirable in formulating a treatment for dyslipidemia.

SUMMARY OF THE INVENTION

20 The présent invention provides compounds capable of altering PPAR activity. Compounds of the présent invention are described by Formula I:

25

I

J 012781 or a pharmaceutically acceptable sait thereof,where: T is a saturated or unsaturated, substituted or unsubstituted hydrocarbon5 chain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein the carbon atom of position 2 is connected to the carbon atom of position 3 to form afive to eight member ring; W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 where 10 Y is CR4R5 or absent when W is O, S, or NR3; and Y is O or absent when W is CH2 or CR4R5; R and R are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR6R7; 15 R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R6 and R7 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl,COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined together 20 to form a 4 to 7 member ring having 1 to 3 heteroatoms; X° and X1 are independently O or S;

Ar1 is substituted or unsubstituted aryl or heteroaryl;m is 0 to 5;n is 0 to 5; and 25 p is 0 to 2.

In one embodiment, the présent invention provides compounds asdescribed by Formula Ha, Formula Ilb, Formula Ile, Formula Hd, or Formula Ile: 4 01278 1

Ha Hb

or a pharmaceutically acceptable sait thereof, 5 012781 where: W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 where Y is CR4R5 or absent when W is O, S, or NR3; and5 Y is O or absent when W is CH2 or CR4R5; R1 and R2 are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR6R7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; 10 R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R and R are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CCharyl, -SO2alkyl, -SOiaryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; 15 ' X° and X1 are independently O or S;

Ar1 is substituted or unsubstituted aryl or heteroaryl;mis Oto 5; . n is 0 to 5;p is 0 to 2; and 20 Y1, Y2, Y3 and Y4 are independently a carbon atom or a heteroatom wherein the carbon atom and the heteroatom are bonded to a sufficient nurnber ofhydrogen atoms or substituents to complété the valency of each atom with theproviso that Y1, Y2, Y3 and Y4 are not ail heteroatoms and that not more than twoadjacent atoms in Y1, Y2, Y3 and Y4 are heteroatoms and that in Formulae Hb, Ile, .25 and Ild, Y1, Y2, Y3 and Y4 are not ail carbon.

In one embodiment, the présent invention provides compounds asdescribed by Formula Ilia or Formula IUb: 6 01278 1

fflc 10 or a pharmaceutically acceptable sait thereof,where: W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 where Y is CR4R5 or absent when W is O, S, or NR3; and 15 Y is O or absent when W is CH2 or CR4R5;

i O R and R" are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR6R7 R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; 7 01278 1 R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R and R are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined together 5 to form a 4 to 7 member ring having 1 to 3 heteroatoms; X° and X1 are independently O or S;

Ar1 is substituted or unsubstituted aryl or heteroaryl;mis0to5;n is 0 to 5; 10 p is 0 to 2; and Z , Z , and Z are independently a carbon atom or a heteroatom whereinthe carbon atom and the heteroatom are bonded to a sufficient number ofhydrogen atoms or substituents to complété the valency of each atom with theproviso that Z1, Z2, and Z3 are not ail heteroatoms and that in Formulae Ilia and 1 r\ <3 15 nib Z , Z , and Z are not ail carbon atoms.

In yet another embodiment of the présent invention, a method of preparingthe compounds of Formula I - ΙΠ is provided. The method of the présentinvention includes reacting

20 in a solvent in the presence of a base such as césium carbonate, with 25 where

8 01278 1 T, R1, R2, R3, R4, R5, R6, R7, X°, X1, Ar1, m, n, and p are the same asdescribed above; X is a halogen; and R10 is a lower alkyl.

In another embodiment of the présent invention a pharmaceuticalcomposition comprising a compound of Formula I and one or morepharmaceutically acceptable carriers, diluents, or excipients is provided.

In another embodiment of the présent invention, a method of treating,preventing or controlling hypercholesteremia in a mammal is provided. Themethod comprises administering to the mammal in need thereof a therapeuticallyeffective amount of the compounds of the présent invention.

In another embodiment of the présent invention a method for treating,preventing, or controlling obesity is provided.

In another embodiment of the présent invention a method for treating,preventing, or controlling hyperglycexnia is provided.

In another embodiment of the présent invention a method for treating,preventing, or controlling atherosclerosis is provided.

In another embodiment of the présent invention a method for treating,preventing, or controlling hypertriglyceridemia is provided.

In another embodiment of the présent invention a method for treating,preventing, or controlling hyperinsulinemia is provided.

In another embodiment of the présent invention a method for treating, -preventing, or controlling diabètes is provided.

In another embodiment of the présent invention a method for treating apatient exhibiting glucose disorders associated with circulating glucocorticoids,growth hormone, catecholamines, glucagon, or parathyroid hormone is provided.

For each disease state treatable, preventable, or controllable by the methodof the présent invention, a therapeutically effective amount of the compounds ofthe présent invention are administered to the mammal in need thereof.

In yet another embodiment of the présent invention, a method forpreparing compounds of Formula I is provided. 9 012781

DETAILED DESCRIPTION OF THE INVENTION

The foliowing définitions are used, unless otherwise described·. alkyl,alkoxy, alkenyl, alkynyl, etc. dénoté both straight and branched groups; butréférencé to an individual radical such as "propyl" embraces only the straightChain radical, a branched chain isomer such as "isopropyl" being specifîcallyreferred to.

The terni “alkyl” as used herein refers to a straight or branched.hydrocarbon of from 1 to 11 carbon atoms and includes, for example, methyl,ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, iert-butyl, n-pentyl,n-hexyl, and the like. The alkyl group can also be substituted with one or more ofthe substituents selected from lower alkoxy, lower thioalkoxy, -0(CH2)o-2CF3,halogen, nitro, cyano, =0, =S, -OH, -SH, -CF3, -CO2H, -CO2Ci-C6 alkyl, -NH2,-NHCi-Cô alkyl, -CONR’R”, or -N(Cj-C6alkyl)2 where R’ and R” areindependently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7memb'er ring. Useful alkyl groups hâve from 1 to 6 carbon atoms (Cj-Cô alkyl).

The terni “lower alkyl” as used herein refers to a subset of alkyl whichmeans a straight or branched hydrocarbon radical having from 1 to 6 carbon atomsand includes, for example,_methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,isobutyl, fôri-butyl, n-pentyl, n-hexyl, and the like. Optionally, lower alkyl isreferred to as “Ci-Côalkyl.” 2

The term “alkenyl” means a straight or branched unsaturated hydrocarbonradical having from 2 to 12 carbon atoms and includes, for example, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, 1-undecenyl, 1-dodecenyl, and the like.

The term “alkynyl” means a straight or branched hydrocarbon radicalhaving from 2 to 12 carbon atoms having at least one triple bond and includes, forexample, 1-propynyl, 1-butynyl, 3-butynyl, 1-pentynyl, 3-pentynyl, 3-methyl-3- 10 0127 8 1 butynyl, 1-hexynyl, 3-hexynyl, 3-hexynyl, 3-heptynyl, 1-octynyl, 1-nonynyl, 1-decynyl, 1-undecynyl, 1-dodecynyl, and the like.

The term "alkylene" as used herein refers to a divalent group derived froma straight or branched chain saturated hydrocarbon having from 1 to 10 carbonatoms by the removal of two hydrogen atoms, for example methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, 2,2- dimethylpropylene, and the like. Thealkylene groups of this invention can be optionally substituted. The alkylenegroup can also be substituted with one or more of the substituents selected from. lower alkyl, lower alkoxy, lower thioalkoxy, -0(CH2)o-2CF3, halogen, nitro,cyano, =0, =S, -OH, -SH, -CF3, -CO2H, -CO2C,-Ç6 alkyl, -NH2, -NHC,-C6 alkyl,-CONR’R”, or -N(C]-C6alkyl)2 where R’ and R” are independently alkyl, akenyl,alkynyl, aryl, or joined together to form a 4 to 7 member ring. Useful alkylenegroups hâve from 1 to 6 carbon atoms (Cj-Cg alkylene).

The term “halogen” includes chlorine, fluorine, bromine, and iodine. $

The term “heteroatom” as used herein represents oxygen, nitrogen, orsulfur (O, N, or S) as well as sulfoxyl or sulfonyl (SO or SO2) unless otherwiseindicated. . The term “heteroalkyl” as used herein, refers to an alkyl group thatincludes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with 1valence completed by hydrogen or oxygen) in the carbon chain or terminating thecarbon chain.

The term “hydrocarbon chain” as used herein refers to a straighthydrocarbon of from 2 to 6 carbon atoms. The hydrocarbon chain is optionallysubstituted with one or more substituents selected from lower alkyl, lower alkoxy,lower thioalkoxy, -0(CH2)o-2CF3, halogen, nitro, cyano, =0, =S, -OH, -SH, -CF3,-CO2H, -CO2Ci-C6 alkyl, -NH2, -NHC,-Cg alkyl, -CONR’R”, or-N(Ci-Cealkyl)2 where R’ and R” are independently alkyl, akenyl, alkynyl, aryl, orjoined together to form a 4 to 7 member ring. il 01278 1

The terrn “hydrocarbon-heteroatom chain” as used herein refers to ahydrocarbon chain wherein one or more carbon atoms are replaced with aheteroatom. The hydrocarbon-heteroatom chain is optionally substituted with oneor more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -0(CH2)o-2CF3, halogen, nitro, cyano, =0, =S, -OH, -SH, -CF3, -CO2H, -CO2CrC6 alkyl, -NH2, -NHC,-C6 alkyl, -CONR’R”, or -N(C,-C6alkyl)2 whereR’ and R” are independently alkyl, akenyl, alkynyl, aryl, or joined together toform a 4 to 7 member ring.

The term "heteroalkylene" as used herein, refers to an alkylene radical asdefined above that includes one or more heteroatoms such as oxygen, sulfur, ornitrogen (with valence completed by hydrogen or oxygen) in the carbon chain orterminating the carbon chain.

The terms “lower alkoxy” and “lower thioalkoxy” as used herein refers toO-alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for “lower alkyl.”

The term "haloalkyl" as used herein refers to a lower alkyl radical, asdefined above, bearing at least one halogen substituent, for example,chloromethyl, fluoroethyl, or trifluoromethyl, and the like. Haloalkyl can alsoinclude perfluoroalkyl wherein ail hydrogens of a loweralkyl group are replacedwith fluorides.

The term “aryl” as used herein refers to an aromatic ring which isunsubstituted or optionally substituted by 1 to 4 substituents selected from loweralkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano -OH, -SH, -CF3,-CO2H,-CO2C,-C6 alkyl, -NH2,-NHCrC6 alkyl, -SO2alkyl, -SO2NH2, -CONR’R”, or -N(Ci-Côalkyl)2, where R’ and R” are independently alkyl, akenyl,alkynyl, aryl, or joined together to form a 4 to 7 member ring. Examples include,but are not limited to phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-niethoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4- 12 01278 1 methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4-methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2-methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, and îhe like. 5 The term “arylene” as used herein refers to a divalent group derived from an aromatic ring. The arylene group can also be substituted with one or more ofthe substituents listed above for aryl.

The term “heteroaryl” means an aromatic ring containing one or more10 heteroatoms. The heteroaryl is optionally substituted with one or more groups enumerated for aryl. Examples of heteroaryl include, but are not limited to thienyl,furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl,benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, and quinazolinyl,and the like. 15

The term "cycloalkylene" as used herein refers to a divalent group deriveds from a cyclic saturated hydrocarbon having from 3 to 8 carbon atoms by theremoval of two hydrogen atoms. The cycloalkylene groups of this invention canbe optionally substituted. The alkylene group can also be substituted with one or 20 more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -0(CH2)o-2CF^, halogen, nitro, cyano, =O, =S, -OH, -SH, -CF3, -OCF3, -CO2H, -CO2C,-e6 alkyl, -NH2, -NHC,-C6 alkyl, -CONR’R”, or-N(C]-Côalkyl)2 where R’ and R” are independently alkyl, akenyl, alkynyl, aryl, orjoined together to form a 4 to 7 member ring. Useful cycloalkylene groups hâve 25 from 3 to 6 carbon atoms (C3-C6 alkyl).

The term “heterocycloalkylene” as used herein, refers to a cycloalkylenegroup that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen(with valence completed by hydrogen or oxygen) in the carbon chain or 30 terminating the carbon chain.

The term “heterocycle” means a saturated or unsaturated mono- orpolycyclic (i.e. bicyclic) ring incorporating one or more (i.e. 1-4) heteroatoms 13 012781 selected from N, O, and S. It is understood that a heterocycle is optionallysubstituted with -OH, -O(alkyl), SH, S(alkyl), amine, halogen, acid, ester, amide,amidine, alkyl ketone, aldéhyde, nitrile, haloalkyl, nitro, sulphone, sulfoxide or Cj.Cô alkyl. Examples of suitable monocyclic heterocycles include, but are notlimited to substituted or unsubstituted thienyl, furanyl, pyrrolyl, imidazolyl,pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazoiyl, tetrazolyl,pyridinyl, pyrazinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, azetidinyl,aziridinyl, morpholinyl, thietanyl, oxetaryl. Examples of monocyclic heterocyclesinclude, but are not limited to, 1-, 2-, 4-, or 5-imidazolyl, 1-, 3-, 4-, or 5-pyrazoIyl,.2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 1, 3-, or 5-triazolyl, 1-, 2-, or 3-tetrazolyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 1- or 2-piperazinyl, 2-, 3-, or 4-morpholinyl. Examples of suitablebicyclic heterocycles include, but are not limited to indolizinyl, isoindolyl,benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, quinolinyl,isoquinolinyl, quinazolinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 1-, 2-, 3-, 5-, 6-, 7-, or8-indolizinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzolhienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 1-, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl.

The term “cycloalkenyl” means a cycloalkyl group having one or morecarbon-carbon double bonds. Example includes cyclobutene, cyclopentene,cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, and the like.

The term “heterocycloalkyl” means a nonaromatic ring with from 4 to 8members, with up to 4 heteroatoms for example, N, O, and S. Examples ofheterocycloalkyl, include but are not limited to, 2- or 3-tetrahydrothieno, 2- or 3-tetrahydrofurano, 2- or 3-pyrrolidino, 2-, 4-, or 5-thiazolidino, 2-, 4-, or 5-oxazolidino, 2-, 3-, or 4-piperidino, N-morpholinyl or N-thiamorpholinyl ortetrahydropyrano.

The term “cycloalkyl” means a saturated hydrocarbon ring, and includesfor example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and u 012781 cyclooctyl, and the like. The cycloalkyl group is optionally substituted with 1 to3 substituents from the group of substituents described above for aryl. Usefulcycloalkyl include those having from 3 to 8 carbon atoms.

The terni “patient” means ail mammals including humans. Examples ofpatients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. A “therapeutically effective amount” is an amount of a compound of theprésent invention that when administered to a patient améliorâtes a symptom ofdyslipidemia, non-insulin dépendent diabètes mellitus, obesity, hyperglycemia,hypercholesteremia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, orhyperinsulinemia.

The term “a pharmaceutically acceptable sait” refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the présentinvention. These salts can be prepared in situ during the final isolation andpurification of the compounds or by separately reacting the purified compound inits free base form with a suitable organic or inorganic acid and isolating the saitthus formed. Représentative salts include the hydrobromide, hydrochloride,sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stéarate,laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, andlaurylsulphonate salts, and the like. These also. include cations based on the alkaliand alkaline earth metals, such as sodium, lithium, potassium, calcium,magnésium, and the like, as well as non-toxic ammonium, quatemary ammonium,and amine cations including, but not limited to ammonium, tétraméthylammonium, tetraethylammonium, methylamine, dimethylamine,trimethylamine, triethylamine, ethylamine, and the like. (See, for example,

Berge S.M., et al., “Pharmaceutical Salts,” J. Pharm. Sri., 1977;66:1-19, which isincorporated herein by reference.) The free base form may be regenerated bycontacting the sait form with a base. While the free base may differ from the saitform in terms of physical properties, such as solubility, the salts are équivalent totheir respective free bases for the purposes of the présent invention. 15 012781

The présent invention provides compounds capable of altering PPARactivity having Formula I:

I or a pharmaceutically acceptable sait thereof,where:. T is a saturated or unsaturated, substituted or unsubstituted hydrocarbonchain èr hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein thecarbon atom of position 2 is connected to the carbon atom of position 3 to form afïve to eight member ring; W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 wherein Y is CR4R5 or absent when W is O, S, or NR3; and Y is O or absent when W is CH2 or CR4R5; 1 “1 R and R" are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-0-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)„,NR6R7, -COR3, -CO2H, -CO2R3, or-NRôR7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R and R are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R and R are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; X° and X1 are independently O or S; 16 012781

Ar1 is substituted or unsubstituted aryl or heteroaryl;m is 0 to 5;nis0to5;andp is 0 to 2.

In the présent embodiment, T is optionally substituted with 1 or moresubstituents selected from the group consisting of lower alkyl, lower alkoxy,lower thioalkoxy, -0(CH2)o-2CF3, halogen, nitro, cyano, =0, =S, -OH, -SH,-CF3, -CO2H, -CO2C,-C6 alkyl, -NH2, -NHC,-C6 alkyl, -OCH2O-, and-N(CrC6alkyl)2.

Examples of T include, but are not limited to, -CH2CH2CO-O-, -CH2-CH2-O-CO-, -CH2-CH2-CH2-CH2-, -HC=CH-HC=CH-, -N=CH-HC=CH-, -HC=N-HC=CH-, -HC=CH-N=CH-, -HC=CH-HC=N-, -CH2-CH2-CH2-, -CH2-CH2-O-CH2-, -CH2-HC=CH-CH2-, -CH2-HC=CH-, -CH2CH2-NH-CH2-, -COCH=CH-O-, -O-ÇH=CH-CO-, -CH=CH-NR4-, -NR4-CH=CH-, -CH=CH-CH2-, -CH2-CH2-NR4-, -NR4-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-O-, -CH2-CH2.CO-, -CH2-CO-ch2., -co-ch2-ch2-, -ch2-ch2-ch2-co-, -co-ch2-ch2-ch2-, -ch2-co-ch2-CH2-, -CH2-CH2-CO-CH2-, -CH2-CH2-CH2-NR4-, -NR4-CH2-CH2-CH2-, -0-CH2-ch2-ch2-, -ch2-ch2-ch2-o-, -co-nr4-ch2-ch2-, nr4co-ch2-ch2-, -ch2-CH2_NR4-CO-, and -CH2^CH2-CO-NR4-. It will be understood that the left-mostatom'of these groups in attached to the atom labeled “3” in Formula I and thejight-most atom of these groups is attached to the atom label “2” in Formula I.

Examples of compounds of Formula I include those where W is O, Y isabsent, and n is 1.

Additional Examples of compounds of Formula I include those where R1 and R2 are independently hydrogen, alkyl, or alkoxy. Examples of compounds of10

Formula I where R and R" are independently alkyl include, but are not limited to,10 those where R and R are independently methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl. Examples of compounds of Formula I where R1 and R2 17 012781 are independently alkoxy include, but are not limited to, those where R1 and R2are independently methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, orisobutoxy.

Additional Examples of compounds of Formula I include those where R1is hydrogen and R2 is alkyl, or alkoxy. Examples of compounds of Formula Iwhere R1 is hydrogen and R2 is alkyl or alkoxy include, but are not limited to,those where R is methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy,isobutoxy, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl.

In yet another example of compounds of the présent invention, T inFormula I is -Υ^Υ’-Υ^Υ1-, -Y4-Y3-Y2-Y1-, -Y4=Y3-Y2-Y1-, -Y4-Y3-Y2=Y1-, or-Y4-Y3=Y2-Y1-. Examples of compounds of the invention where T in Formula Iis -y4=y3-y2=y’-, -γ4-γ3-γ2-γ1-, -Y4=Y3-Y2-Y\ -Y4-Y3-Y2=Y1-, or-Y4-Y3=Y2-Y’- include, but are notlimited to compounds of Formula Ha, Formula Kb,Formula Hc, Formula Ild, and Formula De:

18 01278 1

Hé or a pharmaceutically acceptable sait thereof, where: W, Y, R1, R2, R4, R5, R6, R7, X°, X1, Ar1, m, n, and p are the same as defined above for Formula I; and Y1, Y2, Y3 and Y4 are each independently a carbon atom or a heteroatomwherein the carbon atom and the heteroatom are bonded to a sufficient number of 15 hydrogen atoms or substituents as listed above for T to complété the valency ofeach atom with the proviso that Y1, Y2, Y3 and Y4 are not ail heteroatoms and thatnot more than two adjacent atoms in Y1, Y2, Y3 and Y4 are heteroatoms and that inFormulae Hb, De, and Ild, Y1, Y2, Y3 and Y4 are not ail carbon. 19 012781

Examples of compounds of Formula H, Formula Ha, Formula Ilb,Formula Ile, Formula Ild and Formula De, include those where W is O, Y isabsent, and n is 1. 5 Additional Examples of compounds of Formula II, Formula lia. Formula

Db, Formula Ile, Formula Ild and Formula Ile include those where R1 and R2 areindependently hydrogen, alkyl, or alkoxy. Examples of compounds of Formula Iwhere R1 and R2 are independently alkyl include, but are not limited to, thosewhere R1 and R2 are independently methyl, ethyl, isopropyl, n-propyl, t-butyl, n- 10 butyl, or isobutyl. Examples of compounds of Formula I where R and R" areindependently alkoxy include, but are not limited to, those where R1 and R2 areindependently methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, orisobutoxy. 15 Additional Examples of compounds of Formula II, Formula Ha, Formula

Hb, Formula Ile, Formula Hd and Formula ïïe include those where R1 is hydrogenand R" is alkyl, or alkoxy. Examples of compounds of Formula ïï, Formula Ha,Formula Hb, Formula De, Formula nd and Formula He where R’ is hydrogen andR2 is alkyl or alkoxy include, but are not limited to, those where R2 is methoxy, 20 ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, isobutoxy, methyl, ethyl,isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl.

In yet another example of compounds of the présent invention, T inFormula I is -Z3=Z2-Z’-, -Z3-Z2=Z5-, or-Z3-Z2-Z1-. Examples of compoundsof 25 the présent invention where T in Formula I is -Z3=Z2-Z!-, -Z3-Z2=Z’-, or -Z3-Z2-Z1- include, but are not limited to, compounds of Formula IHa, Formula IHb, andFormula IHc: 20 012781

Die or a pharmaceutically acceptable sait thereof, where: W, S, R1, R2, R3, R4, R5,·R6,10 R7, Ar1, X°, X1, m, n, and p are the same are provided above for Formula I; and Z , Z", and Z are each independently a carbon atom or a heteroatomwherein the carbon atom and the heteroatom are bonded to a sufficient number ofhydrogen atoms or substituents as listed above for T to complété the valency ofeach atom with the proviso that in Formulae Ilia and fflb Z1, Z2, and Z3 are not ail 15 heteroatoms. In an Example of compounds of Formula IIIc, Z1, Z2, and Z3 are ailcarbon atoms.

Examples of compounds of Formula IH, Formula nia, Formula mb, andFormula IHc, include those where W is O, Y is absent, and n is 1. 21 012781

Additional Examples of compounds of Formula ΙΠ, Formula IHa, FormulaIHb, and Formula Die include those where R and R are independently hydrogen,alkyl, or alkoxy. Examples of compounds of Formula I where R1 and R2 areindependently alkyl include, but are not limited to, those where R1 and R2 areindependently methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl.Examples of compounds of Formula I where R1 and R2 are independently alkoxyinclude, but are not limited to, those where R' and R2 are independently methoxy,ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy.

Additional Examples of compounds of Formula ΠΙ, Formula nia, FormulaIHb, and Formula Die include those where R1 is hydrogen and R2 is alkyl, oralkoxy. Examples of compounds of Formula Π, Formula Ha, Formula Ub,Formula lie, Formula Ild and Formula De where R1 is hydrogen and R2 is alkyl oralkoxy include, but are not limited to, those where R2 is methoxy, ethoxy,isopropoxy, n-propoxy, t-butoxy, n-butoxy, isobutoxy, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl.

Examples of compounds of Formula I include {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-5-oxo-5,6,7,8-tetrahy dro-naphthalen-1 -yloxy} -acetic acid ; {4-[4-MethyI-2-(4'-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-8-oxo-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-7-oxo-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-6-oxo-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-4H-chromen-8-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- 4-oxo-4H-chromen-5-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-chroman-5-yloxy}-acetic acid; 22 012781 {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-chroman-8-yloxy} -acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-quinolin-5-yloxy} -acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-isoquinolin-5-yloxy} -acetic acid; {1 -Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-1 H-benzoimidazol-4-yloxy} -acetic acid; {3-Methyl-7-Î4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-1 H-benzoimidazol-4-yloxy} -acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanylj-lH-indol-4-yloxy}-acetic acid; {1 -Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl] -1 H-indol-4-yloxy ] -acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzo[b]thiophen-4-yloxy}-acetic acid; -$ {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzofuran-4-yloxy}-acetic acid; and pharmaceutically acceptable salts thereof.

Additional examples of compounds of Formula I include{8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- chroman-5-yloxy} -acetic acid; {4-[4-Methyl-2-(4-trifluoiOmethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-5,6,7,8-tetrahydro-naphthalen-1 -yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-naphthalen-1-yloxy}-acetic acid; 2-[6-methyl-8-({4-methyl-2-[4-(trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)chroman-5-yloxy]acetic acid; 2-[5-methyl-7-( {4-methyl-2-[4-(trifluoromethyl)phenyl]( 1,3-thiazol-5-yl)}methylthio)-2,3-dihydrobenzo[b]furan-4-yloxy]acetic acid; {5-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indan-4-yloxy}-acetic acid; and 23 012781 pharmaceutically acceptable salts thereof. A Further example of a compound of Formula I includes {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indan-4-yloxy}-acetic acid; and pharmaceutically acceptable salts thereof.

Certain of the compounds of the présent invention possess one or morechiral centers and each center may exist in the R or S configuration. The présentinvention includes ail diastereomeric, enantiomeric, and epimeric forms as well asthe appropriate mixtures thereof. Stereoisomers may be obtained, if desired, bymethods known in the art as, for example, the séparation of stereoisomers bychiral chromatographie columns.

Additionally, the compounds of the présent invention may exist as géométrieisomers. The présent invention includes ail cis, trans, syn, anti, entgegen (E), andzusammen (Z) isomers as well as the appropriate mixtures thereof.

S

In some situations, compounds may exist as tautomers. Ail tautomers areincluded within Formulae I-IH and are provided by this invention.

The présent invention includes ail pharmaceutically acceptable, non-toxicesters of the compounds of this invention include C;-C6 alkyl esters wherein thealkyl group is a straight or branched chain. Acceptable esters also includeC5-C? cycloalkyl esters as well as arylalkyl esters such as, but not limited tobenzyl. Cj-C alkyl esters are preferred. Esters of the compounds of the présentinvention may be prepared according to conventional methods.

In addition, the compounds of the présent invention can exist in unsolvatedas well as solvated forms with pharmaceutically acceptable solvents such as water,éthanol, and the Iike. In general, the solvated forms are considered équivalent tothe unsolvated forms for the purposes of the présent invention. 24 07278 ί

The compounds of the présent invention are suitable to be administered toa patient for the treatment, control, or prévention of non-insulin dépendentdiabètes mellitus, hypercholesteremia, hyperlipidemia, obesity, hyperglycemia,hyperlipidemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia.Accordingly, the compounds may be administered to a patient alone or as part of acomposition that contains other components such as excipients, diluents, andcarriers, ail of which are welï-known in the art. The compositions can beadministered to humans and/or animais either orally, rectally, parenterally(intravenously, intramuscularly, or subcutaneously), intracisternally,intravaginally, intraperitoneally, intravesically, locally (powders, ointments, ordrops), or as a buccal or nasal spray.

Compositions suitable for parentéral injection may comprisephysiologically acceptable stérile aqueous or nonaqueous solutions, dispersions,suspensions or émulsions, and stérile powders for reconstitution into stérileinjectable solutions or dispersions. Examples of suitable aqueous and nonaqueouscarriers, diluents, solvents or vehicles include water, éthanol, polyols(propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixturesthereof, vegetable oils (such as olive oil), and injectable organic esters such asethyl oleate. Proper fluidity can be maintained, for example, by the use of acoating such as lecithin, by the maintenance of the required particle size in thecase of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving,wetting, emulsifying, and dispensing agents. Prévention of the action ofmicroorganisms can be ensured by various antibacterial and antifungal agents, forexample, parabens, chlorobutanol, phénol, sorbic acid, and the like. It may also bedésirable to include isotonie agents, for example sugars, sodium chloride, and thelike. Prolonged absorption of the injectable pharmaceutical form can be broughtabout by the use of agents delaying absorption, for example, aluminummonostearate and gelatin. 25 012781

Solid dosage forms for oral administration include capsules, tablets, pills,powders, and granules. In such solid dosage forms, the active compound isadmixed with at least one inert customary excipient (or carrier) such as sodiumcitrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches,lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, as for example,carboxymethylcellulose, alignâtes, gelatin, polyvinylpyrrolidone, sucrose, andacacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as forexample, agar, calcium carbonate, potato or tapioca starch, alginic acid, certaincomplex silicates, and sodium carbonate; (e) solution retarders, as for exampleparaffin; (f) absorption accelerators, as for example, quatemary ammoniumcompounds; (g) wetting agents, as for example, cetyl alcohol and glycerolmonostearate; (h) adsorbents, as for example, kaolin and bentonite; and(i) fabricants, as for example, talc, calcium stéarate, magnésium stéarate, solidpolyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case ofcapsules, tablets, and pills, the dosage forms may also comprise buffering agents. 4 Solid compositions of a similar type may also be employed as fillers insoft and hard-fîlled gelatin capsules using such excipients as lactose or milk sugar,as well as high molecular weight polyethyleneglycols, and the like.

Solid dosage forms such as tablets, dragees, capsules, pills, and granulescan be prepared with coatings and shells, such as enteric coatings and otherswell-known in the art. They may contain opacifying agents, and can also be of suchcomposition that they release the active compound or compounds in a certain partof the intestinal tract in a delayed manner. Examples of embedding compositionswhich can be used are polymeric substances and waxes. The active compoundscan also be in micro-encapsulated form, if appropriate, with one or more of theabove-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable émulsions, solutions, suspensions, syrups, and élixirs. In addition to theactive compounds, the liquid dosage forms may contain inert diluents commonlyused in the ail, such as water or other solvents, solubilizing agents and emulsifiers, 26 01278 1 as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate,benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germoil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol,polyethyleneglycols and fatty acid esters of sorbitan or mixtures of thesesubstances, and the like.

Besides such inert diluents, the composition can also include adjuvants,such as wetting agents, emulsifying and suspending agents, sweetening, flavoring,and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspendingagents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitoland sorbitan esters, microcrystalline cellulose, aluminum metahydroxide,bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like. * Compositions for rectal administrations are preferably suppositories whichcan be prepared by mixing the compounds of the présent invention with suitablenon-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or asuppository wax, which are solid at ordinary températures but liquid at bodytempérature and therefore, melt in the rectum or vaginal cavity and release theactive component.

Dosage forms for topical administration of a compound of this inventioninclude ointments, powders, sprays, and inhalants. The active component isadmixed under stérile conditions with a physiologically acceptable carrier and anypreservatives, buffers, or propellants as may be required. Ophthalmicformulations, eye ointments, powders, and solutions are also contemplated asbeing within the scope of this invention.

The compounds of the présent invention can be administered to a patient atdosage levels in the range of about 0.1 to about 2,000 mg per day. For a normalhuman adult having a body weight of about 70 kilograms, a dosage in the range of 27 01278 1 about 0.01 to about 10 mg per kilogram of body weight per day is préférable.However, the spécifie dosage used can vary. For example, the dosage can dépendon a numbers of factors including the requirements of the patient, the severity ofthe condition being treated, and the pharmacological activity of the compoundbeing used. The détermination of optimum dosages for a particular patient is well-known to those skilled in the art.

PREPARATION OF COMPOUNDS OF THE INVENTION

The présent invention contains compounds that can be synthesized in anumber of ways familiar to one skilled in organic synthesis. The compoundsoutlined herein can be synthesized according to the methods described below,along with methods typically utilized by a synthetic chemist, and combinations orvariations of those methods which are generally known to one skilled in the art ofsynthetic chemistry. The synthetic route of compounds in the présent invention isnot limited to the methods outlined below. It is assumed one skilled in the art willbe able to use the schemes outlined below to synthesize compounds claimed inthis invention. Individual compounds may require manipulation of the conditionsin order to accommodate various functional groups. A variety of protectinggroups generally known to one skilled in the art may be required. Purification, ifnecessary, can be accomplished on a silica gel column eluted with the appropriateorganic solvent System. Also, reverse phase HPLC or recrystallization may beemployed if needed.

In still another embodiment of the présent invention, a method ofpreparing the compounds of Formula I - HI is provided. The compounds ofFormulae Ι-ΠΙ can be prepared by reacting:

X°H

28 012781 ' in a solvent in the presence of a base such as césium carbonate with the arylhalide:

Ar wherein T, R1, R2, R3, R4, R5, R6, R7, X°, X1, Ar1, W, Y m, n, and p are the saine as described above; X is a halogen; and R10 is a lower alkyl.

The resulting ester is then converted to the compounds of Formulae I-ΙΠby various methods known in the art for the conversion of esters to acids, such asvia hydrolysis for example. A useful aryl halide, for example, is 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole. The synthetic route tocompounds with Formula Ka-e is provided when T is -Y4=Y3-Y2=Y1-, -Y4-Y3-Y2-Y’-, -γ^γυ^-γ’-,-Y4-Y3-Y2=Y’-, or-Y4-Y3=Y2-Y5- as defined above.The préparation of compounds with Formula Illa-c is provided when T is -Z3=Z2-Z1-, -Z3-Z2=Z’-, or-Z3-Z2-Z’- as defined above.

The compounds of the présent invention can be made by the methods -described in Schemes 1 - 3 for example. Scheme 1 provides an alternativepréparation for compounds of the présent invention. With référencé to Scheme 1,compounds of the general formula A are reacted with trimethylsilylisothiocyanate and phenyliodine(III) bis(trifluoroacetate) to form compounds ofthe general formula B. Compounds of the general formula C are then prepared byréduction of B with dithiothreitol in methanol. Compounds of the general formulaC are then alkylated with the halide compound D to form compound E. A usefularyl halide compound D, for example, is 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole. Compounds of the general formula E are then 29 01278 1 saponified with LiOH in the THF to give the final compound F. Compound Fcorresponds to the compounds of the présent invention described by Formula I.The synthetic route to compounds with Formula Ha-e is provided when T is -Y^-Y^Y’-, -y4.y3-y2.y1., -Y^Y^-Y1-, -Υ4-Υ3-Υ2=Υ'-, or-Y4-Y3=Y2-Y1- as defined above. The préparation of compounds with Formula IHa-c isprovided when T is -Z3=Z2-Z’-, -Z3-Z2=Z1-, or-Z3-Z2-Z’- as defined above.

Scheme 1

phenyliodine(UI) bis(trifluoroacetate) / TMS-NCSthiocy anation dithiothreitol / ,02M KH2PO4réduction

SCN

B X1 Ί

x\ A-\v \ x , I · (CH2)„ 10

SH c

LiOH/HjO/THF saponification

15 Scheme 2 provides a synthetic route to compound A in Scheme 1 when W is O, Y is absent, R10 is methyl, and n is 1. With reference to Scheme 2,compounds of the general formula G are then alkylated with methyl bromoacetateto give compounds of the general formula A’. 311 012781

Scheme 2

OH

G

Cs2CO3/CH3CN alkylation

A’

Scheme 3 provides an alternative synthetic route to compound B inScheme 1 when W is O, Y is absent, R10 is methyl, and n is 1. With reference toScheme 3, compounds of the general formula H are thiocyanated with a mixtureof bromine and sodium thiocyanate to give compounds of the general formula J.Compounds of the general formula J can corne from commercial sources orsynthèses known to those skilled in the art. Compounds of the general formula Jare then alkylated with methyl bromoacetate to give compounds of the generalformula B.

SCN

J

H

Scheme 3

alkylation ^2jf alkylation

SCN

B

Scheme 4 provides yet another alternative method for preparing thecompounds of the présent invention. With reference to Scheme 4, compounds ofthe general formula K are reacted with the potassium triisopropylsilanethiolateand tetrakis(triphenylphosphine) palladium(O) and then reducing the resultingproduct with césium fluoride to produce compounds of general formula C.Compounds of the general formula K can corne from bromination of thecorresponding compound, commercial sources or synthesis’ known to thoseskilled in the art. Compounds of the general formula C are then alkylated with thehalide compound D to form compound E. A useful aryl halide compound D, for 31 012781 example, is 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole.Compounds of the general formula C are then saponifïed with LiOH in tbe THF togive the final compound F. Compound F corresponds to the compounds of theprésent invention described by Formula I. The synthetic route to compounds with 5 Formula Ila-e is provided when T is -Y4=Y3-Y2=Y’-, -Y4-Y3-Y2-Y!-, -Y4=Y3- Y2-Y]-, -Y4-Y3-Y2=Y’-, or-Y4-Y3=Y2-Y!- as defined above. The préparation ofcompounds with Formula Illa-c is provided when T is -Z3=Z2-Z’-, -Z3-Z2=Z’-, or-Z3-Z2-Z]- as defined above. 10

K

Scheme 4 1) TMS-S~K+/ (Ph3P)4Pd 2) CsFthiolation

C

X’V" D

Ar

Cs2CO3/CH3CN alkylation

E

LiOH/HZO/THFsaponification

15

The following non-limiting descriptions also demonstratemethods for thesynthesis of compounds ofFormulae I-ÏÏI. 20 32 01278 1

Example 1 5 Synthesis of {8-i4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethvlsulfanvll-chroman-5-yloxyl-acetic acid (compound 1)

10 Préparation of Chroman-5-ol (compound IA)

OH

IA 15 20

To a solution of 5-hydroxy-chromen-4-one (7. Het. Chem, 13,1976,211) (2.5 g,15.4 mmol) and 1 mL HCI(c) in 75 mL de-gassed EtÔH/THF (3:1) was added0.5g 10% Pd/C. The reaction mixture was stirred at room température for 20 hunder an atmosphère of 1 atm H2(g). The Pd/C was then filtered off, the filtratecollected and concentrated in vacuo to give 2.1 g (91%) of the title compoundpure enough for subséquent use. 400 MHz ’H NMR (DMSO-dô) δ 9.27 (s, 1H), 6.76 (t, 1H, 7=8.1 Hz), 6.26 (d, 1H,7=8.1 Hz), 6.12 (d, 1H,7=8.1 Hz), 3.98 (t,2H, 7 = 5.0 Hz), 2.46 (m, 2H), 1.80 (m, 2H). 25 33 012781

Préparation of (Chroman-5-yloxy)-acetic acid methyl ester (compound IB)

IB A solution of chroman-5-ol (2.1 g, 14 mmol), methyl bromoacetate (1.6 mL, 16.8mmol), and césium carbonate (6.8 g, 21 mmol) in 50 mL acetonitrile was heatedat 60 °C for 3 hours. PS-Trisamine scavenger resin was then added to the warmedsolution followed by an additional 30 minutes heating. The reaction mixture wasthen cooled and fïltered. The filtrate was collected, diluted with 100 mL ether,washed with brine (1 x 50 mL), dried (NaoSCL), and the solvent removed in vacuoto give 2.1 g (68%) of the title compound, pure enough for subséquent use. 400 MHz ’H NMR (DMSO-Jô) δ 6.92 (t, 1H, J = 8.3 Hz), 6.33 (d, 1H, J= 8.3 Hz), 6.31 (d, 1H, 7= 8.3 Hz), 4.72 (s, 2H), 4.02 (t, 2H, 7= 5.1 Hz), 3.64 (s, 3H), 2.56(t, 2H, 7 = 6.6 Hz), 1.83 (m, 2H).

Préparation of (8-Thiocyanato-chroman-5-yloxy)-acetic acid methyl ester(compound IC)

SCN

IC A stirred solution of (chroman-5-yloxy)-acetic acid methyl ester (2.1 g, 9.4 mmol)and trimethylsilyl isothiocyanate (2 mL, 14.1 mmol) in 30 mL 1,1,1,3,3,3-hexafluoro-propan-2-ol under a No atmosphère was treated with phenyliodine(IH)bis(trifluoroacetate). The reaction mixture stirred at room température for 1 h andconcentrated in vacuo. Purification by flash column chromatography (gradientelution: 10% EtOAç/hexanes to 40% EtOAc/bexanes) gave the title compound(1.3 g, 50 %) as a pale yellow solid. 400 MHz ’H NMR (DMSO-4) δ 7.31 (d, 34 012781 1H, J = 8.8 Hz), 6.54 (d, 1H, J = 8.8 Hz), 4.83 (s, 2H), 4.21 (t, 2H, J = 4.9 Hz),3.64 (s, 3H), 2.60 (t, 2H, J= 6.4 Hz), 1.89 (xn, 2H). 5 Préparation of (8-Mercapto-chroman-5-yloxy)-acetic acid niethyl ester(compound 1D)

sh 1D A solution of (8-thiocyanatO'Chroman-5-yloxy)-acetic acid methyl ester (1.3 g, 4.6 10 nunol), dithiothreitol (910 mg, 6 mmol), and KH2PO4 (4.6 mL of a .02M solution)in 30 mL MeOH was heated at reflux for 1 hour after which time the reaction wascooled and concentrated in vacuo. Purification by flash column chromatography(gradient elution: 10% EtOAc/hexanes to 35% EtOAc/hexanes) gave the titlecompound (710 mg, 61 %) as a pale yellow solid. 400 MHz *H NMR (DMSO- 15 d6) δ 6.97 (d, 1H, J= 8.5 Hz), 6.31 (d, 1H, 7= 8.5 Hz), 4.70 (s, 2H), 4.40 (s, 1H), 4.11 (t, 2H, 7 = 5.4 Hz), 3.63 (s, 3H), 2.56 (t, 2H, 7= 6.3 Hz), 1.84 (m, 2H).; MSm/z 255 (M+l).

Préparation of {8-[4-MethyI-2-(4-trifluoromethyl-phenyl)-thiazol-5- 20 ylmethylsulfanyl]-chroman-5-yloxy)-acetic acid methyl ester (compound! 1E) 3 ï i î « 3 ? 3 3 35

1.6 mmol), 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole (564mg, 1.9 mmol) and césium carbonate ( 787 mg, 2.4 mmol) in 15 ml anhydrousacetonitrile were stirred at 60 °C for 2.5 hours. The reaction was then cooled,filtered and concentrated in vacuo. Purification of the residue by flash columnchromatography (gradient elution: 10% EtOAc/hexanes to 35% EtOAc/hexanes)afforded the title compound (95%). IR (thin film) cm'1: 1759; 400 MHz ]HNMR (DMSO-rf6) δ 7.98 (d, 2H, J= 8.3 Hz), 7.75 (d, 2H, 7= 8.3 Hz), 6.96 (d,1H, 7= 8.6 Hz), 6.29 (d, 1H, 7= 8.6 Hz), 4.72 (s, 2H), 4.19 (s, 2H), 4.12 (t, 2H, 7= 5.1 Hz), 3.61 (s, 3H), 2.56 (t, 2H, 7= 6.6 Hz), 2.15 (s, 3H), 1.84 (m, 2H).; MSm/z 510 (M+l). Anal. Calc’d for C24H22F3NiO4S2 C, 56.57; H, 4.35; N, 2.75;found: C, 56.45; H, 4.27;. N, 2.68.

Préparation of {8-[4-Methyl-2-(4-trifluoromethyI-phenyl)-thiazol-5- 1ylmethyIsuIfanyl]-chroman-5-yIoxy}-acetic acid (compound 1) {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-chroman- 5-yloxy}-acetic acid methyl ester dissolved in 5 ml THF and 1 ml water, wastreated with lithium hydroxide monohydrate (327 mg, 7.8 mmol); stirring at roomtempérature for 1 hour. The reaction mixture was then acidified to about pH 3with 2 N HCl. The reaction was then extracted into ethyl acetate (2x20 ml). Theorganic extracts were washed with brine, dried over anhydrous sodium sulfate,decanted, and concentrated in vacuo. Recrystalization from chloroform / hexanes 36 012781 afforded the title compound (750 mg, 96%) as a pale yellow solid. IR (thin film)cm'1: 1745; 400 MHz Ή NMR (DMSO-cfe) δ 7.98 (d, 2H, J = 8.0 Hz), 7.75 (d,2H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.5 Hz), 6.27 (d, 1H, J = 8.5 Hz), 4.60 (s, 2H),4.18 (s, 2H), 4.11 (t, 2H, J = 4.6 Hz), 2.56 (t, 2H, J =6.6 Hz), 2.15 (s, 3H), 1.83 5 (m, 2H).; MS m/z 496 (M+l). Anal. Calc’d for CaHaoFsN^Sa 0.3 CHC13 C, 52.67; H, 3.85; N, 2.64; found: C, 52.49; H, 3.77; N, 2.54. 10 Example 2

Synthesisof {4-r4-MethyI-2-(4-trifluoromethyl-phenvl)-thiazol-5- ylmethylsulfanvn-5,6,7.,8-tetrahydro-naphthalen-l-yloxy)-acetic acid (compound 2) 15

Préparation of 4-Thiocyanato-5,6,7,8-tetrahydro-naphthalen-l-ol (compound2A) 20

5,6,7,8-Tetrahydro-naphthalen-l-ol (lg, 6.8 mmol) was dissolved in 25 mlMeOH. Sodium thiocyanate (1.76 g, 22 mmol) and sodium bromide (0.7 g, 6.S 25 mmol) were added and stirred for 5 minutes at ambient température. Bromine (1.2 g, 7.48 mmol) was added drop wise over 5 minutes. The orange solution wasallowed to stir two hours. Brine was added and the crude product was extractedtwice into ethyl acetate. The combined organic extracts were washed once withbrine, dried over anhydrous sodium sulfate, decanted and concentrated. Normal 37 012781 phase chromatography afforded the title product, 1.28 g, 92%. 400 MHz ’H NMR(DMSO-dg) δ 11.1 (s, 1H), 7.40 (d, 1H, J = 8.8 Hz), 6.61 (d, 1H, 8.8 Hz), 2.78 (m,2H), 2.59 (m, 2H), 1.70 (m, 4H). MS m/z 2ΊΖ (m+1 )

Préparation of (4-Thiocyanato-5,6,7,8-tetrahydro-naphthalen-l-yloxy)-aceticacid methyl ester (compound 2B)

NCS

2B

The title compound was prepared in the manner analogous to example IB utilizingcompound 2A. 400 MHz ’H NMR (DMSO-J6) δ 7.4 (d, 1H, J = 8.8 Hz), 6.80 (d,1H, 8.8 Hz), 4.84 (s, 2H), 3.64 (s, 3H), 2.78 (m, 2H), 2.59 (m, 2H), 1.70 (m, 4H).MS m/z 278 (m+1).

Préparation of (4-Mercapto-5,6,7,8-tetrahydro-naphthalen-l-yloxy)-acetic acid methyl ester (compound 2C)

HS

2C

The title compound was prepared in the manner analogous to example 1Dutilizing compound 2B. 400 MHz ’H NMR (DMSO-d6) δ 7.08 (d, 1H, J = 8.8Hz), 6.55 (d, 1H, 8.8 Hz), 4.71 (s, 1H), 4.70 (s, 2H), 3.63 (s, 3H), 2.45 (m, 2H),2.44 (m, 2H), 1.65 (m, 4H). MS m/z 253 (M+1). 38 012781

Préparation of {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsuIfanyI]-5,6,7,8-tetrahydro-naphthaIen-l-yIoxy}-acetic acid methylester (2D) o

The title compound was prepared in the manner analogous to example 1E utilizingcompound 2C. 400 MHz Ή NMR (DMSO-cfc) δ 7.98 (d, 2H, J = 8 Hz), 7.76 (d,2H, 7 = 8 Hz), 7.11 (d, 1H, J = 8.8 Hz), 6.61 (d, 1H, J = 8.8 Hz), 4.74 (s, 2H), 4.22(s, 2H), 3.62 (s, 3H), 2.63 (m, 2H), 2.55 (m, 2H), 1.59 (m, 4H). MS m/z 508(M+l).

Préparation of {4-[4-MethyI>2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyIsuIfanyl]-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid(compound 2)

The title compound was prepared in the manner analogous to example 1 utilizingcompound 2D. mp 166-Î67 °C; IR (thin film) cm'1: 2928, 1744,1711,1326, . 1245,1118; 400 MHz Ή NMR (DMSO-4) δ 12.93 (br, 1H), 8.00 (d, 2H, X= 8Hz), 7.76 (d, 2H, 7 = 8 Hz), 7.13 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 8.4 Hz), 4.62(s, 2H), 4.22 (s, 2H), 2.63 (m, 2H), 2.54 (m, 2H), 1.58 (m, 4H). MS m/z 494(M+l). Anal. Calc’d for C^HooFsNCbSz C, 58.40; H, 4.49; N, 2.84; found: C,58.10; H, 4.38; N, 2.80. 39 01278 1

Example 3

Synthesis of {4-F4-MethyI-2-(4-trifluoroinethyI-phenvl)-thiazoI-5- vlmethylsulfanyl]-naphthalen-l-yloxy)-acetie acid fcompound 3)

Préparation of 4-Thiocyanato-naphthaIen-l-ol (compound 3A)

NCS

OH

3A

The titîe compound was prepared in the manner analogous to example 2A. 400MHz Ή NMR (DMSO-d6) δ 11.09 (s, 1H), S.20 (d, 1H, J = 8.4 Hz), 8.17 (d, 1H,J = 8.4 Hz), 7.84 (d, 1H, J = 8 Hz), 7.74 (m, 1H), 7.58 (m, 1H), 6.91 (d, 1H, J = 8Hz). MS m/z 202 (m+1).

Préparation of (4-Thiocyanato-naphthaIen-l-yioxy)-acetic acid methyl ester(3B)

3B

The title compound was prepared in the manner analogous to example IB utilizingcompound 3A. 400 MHz ’H NMR (DMSO-J6) δ 8.31 (d, 1H, J = 8.4 Hz), 8.22(d, 1H, J = 8.4 Hz), 7.95 (d, 1H, J = 8 Hz), 7.81 (m, 1H), 7.69 (m, 1H), 7.01 (d, 1H, J = 8 Hz), 5.08 (s, 2H), 3.69 (s, 3H). MS m/z 274 (m+1). 40 012781

Préparation of (4-Mercapto-naphthalen-l-yloxy)-acetic acid methyl ester(compound 3C)

The title compound was prepared in the manner analogous to example 1Dutilizing compound 3B. 400 MHz Ή NMR (DMSO-^s) δ 8.20 (d, 1H, J = 8.4Hz), 8.05 (d, 1H, J = 8.4 Hz), 7.60 (m, 1H), 7.56 (m, 1H), 7.50 (d, 1H, J = 8 Hz),6.8 (d, 1H, J = 8 Hz), 5.32 (s, 1H), 4.94 (s, 2H), 3.67 (s, 3H). MS m/z 249 (m+1).

Préparation of {4-[4-Methyl-2-(4-trifluoromethyI-phenyl)-thiazoI-5-ylmethylsulfanyl]-naphthalen-l-yloxy}-acetic acid methyl ester (compound3D)

The title compound was prepared in the manner analogous to example 1E utilizingcompound 3C. 400 MHz ’H NMR (DMSO-rf6) δ 8.29 (d, 1H, J = 8.4 Hz), 8.21(d, 1H, J = 8 Hz), 7.93 (d, 2H, J = 8 Hz), 7.74 (d, 2H, J = 8.4 Hz), 7.55 (m, 2H),7.49 (d, 1H, J = 8 Hz), 6.81 (d, 1H, J = 8Hz), 4.97 (s, 2H), 4.23 (s, 2H), 3.65 (s,3H), 1.86 (s, 3H). MS m/z 504 (M+1).

Préparation of {4-[4-Methyl-2-(4-trifïuoromethyI-phenyl)-thiazol-5-ylmethylsulfanyl]-naphthalen-l-yloxy}-acetic acid (Compound 3)

The title compound was prepared in the manner analogous to example 1 utilizingcompound 3D. mp 181-183 °C; IR (thin film) cm’1: 2924, 1719, 1323, 1110; 400MHz ’H NMR (DMSO-4) δ 13.1 (br, 1H), S.28 (d, 2H, J = 7.2 Hz), 8.22 (d, 2H,J = 7.2 Hz), 7.94 (d, 2H, J = S Hz), 7.75 (d, 2H, J = 8 Hz), 7.54 (m, 2H), 7.52 (d,1H, J = 8 Hz), 6.80 (d, 1H, J = 8 Hz), 4.85 (s, 2H), 4.29 (s, 2H) 1.87 (s, 3H). MS 41 θ1278 1 m/z 490 (M+l). Anal. Calc’d for C24Hi8F3NO3S2 C, 58.88; H, 3.71; N, 2.86;found: C, 58.40; H, 3.62; N, 2.76.

Example 4

Svnthesis of 2-f6-methyl-8-({4-methyl-2-i4-(trifluoromethyI)phenyll(l,3- thiazol-5-yl))methylthio)chroman-5-yloxylacetic acid (Compound 4)

Préparation of 5-methoxy-2-methyIphenol (Compound 4A)

OH

15 I

4A A mixture of 2-hydroxy-4-methoxy-benzaldehyde (30.4 g, 0.20 mol),palladium/carbon (10%, 50% water, 30 g), concentrated HCl (15 ml) in 1500 ml 20 of ethyl acetate was hydrogenated at 50 psi, at room température overnight, thenfiltered through Celite®. The filtrate was washed with water, brine, dried oversodium sulfate, concentrated, and purified using normal phase chromatography.400 MHz 'H NMR (CDC13) δ 7.01 (d, 1H), 6.44-6.38 (m, 2H), 4.65 (s, 1H), 3.79(s, 3H), 2.18 (s, 3H). 42 012781

Préparation of 4-methoxy-l-methyI-2-perhydropyran-2-yloxybenzene(Compound 4B)

4B

To a solution of the product from example 4A (18.6 g, 0.135 mol) in dichloromethane (250 ml) was added 3,4-dihydro-2Z7-pyran (28.4 g, 0.338 mol)and pyridinium p-toluenesulfonate (1.70 g, 6.75 mmol) at room température. Thissolution was stirred at room température ovemight, then quenched with saturatedsodium bicarbonate (40 ml). The organics were separated, and the aqueous wasextracted twice with dichloromethane (100 ml). The combined organics werewashed with brine, dried over sodium sulfate, and concentrated to give 4B in goodpurity. 400 MHz *H NMR (CDC13) δ 7.04 (d, 1H), 6.72 (d, 1H), 6.44 (dd, 1H),5.40 (t, 1H), 3.92 (m, 1H), 3.76 (s, 3H), 3.61 (m, 1H), 2.19 (s, 3H), 2.02 (m, 1H),1.88 (m,2H), 1.65 (m,3H).

Step 3. Préparation of 3-iodo-4-methoxy-l-methyl-2-perhydropyran-2-yloxybenzene (Compound 4C)

To a solution of the product from example 4B (27.1 g, 0.122 mol) in heptane (500ml) was added butyllithium (2.5 M solution in hexanes, 73.2 ml, 0.183 mol) at 0 43 01278 1 °C. The solution was stirred at 0 °C for 3 h, then a solution of iodine (52.6 g) in600 ml of diethyl ether was added slowly at 0 °C. The reaction mixture wasstirred at 0 °C for 30 minutes, then quenched with saturated sodium thiosulfate(800 ml), and extracted with diethyl ether (3 x 800 ml). The combined organicswere washed with sodium thiosulfate, brine, dried over sodium sulfate, andconcentrated to give 4C in good purity. 400 MHz ’H NMR (CDC13) δ 7.10 (d,1H), 6.58 (d, 1H), 5.08 (m, 1H), 4.17 (m, 1H), 3.89 (s, 3H), 3.52 (m, 1H), 2.38 (s,3H), 2.16-1.24 (m, 6H).

Préparation of 2-iotïo-4-methy]-3-perhydropyran-2-yloxyphenoI (Compound4D)

Sodium ethanethiolate (80%, 12.62 g, 0.12 mol) was added to a solution of theproduct from example 4C (20.88 g, 0.06 mol) in 200 ml of l-methyl-2-pyiTolidinone at room température, then the mixture was heated at 160 °C for 20minutes. After cooling, 2 N HCl was added to pH 6 ~ 7, and extracted with ethylacetate\ The organics were washed with brine, dried over sodium sulfate,concentrated, and purified using normal phase chromatography to afford the titleproduct. 400 MHz ’H NMR (CDC13) δ 7.02 (d, 1H), 6.76 (d, 1H), 5.30 (s, 1H),5.03 (m, 1H), 4.16 (m, 1H), 3.55 (m, 1H), 2.35 (s, 3H), 2.04-1.62 (m, 6H).

Préparation of 4-(3-bromopropoxy)-3-iodo-l-methyl-2-perhydropyran-2-yloxybenzene (Compound 4E) 1

4E

To the product from example 4D (20.04 g, 0.06 mol) in 200 ml of DMF wasadded sodium hydride (60% in minerai oiî, 4.8 g, 0.12 mol) portionwise at 0 °C, 44 012781 then stirred at room température for 30 minutes. 1,3-Dibromopropane (14.54 g,0.072 mol) was added and the mixture was stirred at room température for 30minutes, then poured onto ice, extracted with diethyl ether, washed with brine,dried over sodium sulfate, concentrated, and purified using normal phase 5 chromatography to afford the title product. 400 MHz ’H NMR (CDCI3) δ 7.06 (d,1H), 6.58 (d, 1H), 5.09 (m, 1H), 4.14 (m, 3H), 3.74 (t, 2H), 3.55 (m, 1H), 2.39 (m,2H), 2.37 (s, 3H), 2.16-1.62 (m, 6H).

Préparation of 6-methyl-5-perhydropyran-2-yloxychromane (Compound 4F) 10

4F

To the product from example 4E (13.65 g, 0.030 mol) in 250 ml of THF wasadded butyllithium (2.5 M solution in hexanes, 13.2 ml, 0.033 mol) dropwise at - 15 78 °C, and stirred at the same température for 30 minutes, then quenched with saturated ammonium chloride solution, warmed to room température, extractedwith diethyl ether, washed with brine, dried over sodium sulfate, concentrated,and purified using normal phase chromatography to afford the title product. 400MHz ’H NMR (CDCb) δ 6.89 (d, 1H), 6.56 (d, 1H), 4,83 (m, 1H), 4.10 (m, 3H), 20 3.55 (m, 1H), 2.92 (m, 1H), 2.76 (m, 1H), 2.22 (s, 3H), 1.96-1.60 (m, 8H). 2 45 01278 1

Préparation of 6-methyIchroman-5-ol (Compound 4G)

OH

4G

The mixture of the product from example 4F (94.96 g, 0.02 mol) and pyridiniump-toluenesulfonate (600 mg) in éthanol (200 ml) was heated at 70 °C for 2 h, thencooled to room température, and the solvent was removed in vacuo. The residuewas dissolved in ethyl acetate, washed with brine, dried over sodium sulfate, andconcentrated to give 4G in good purity. 400 MHz ’H NMR (CDCI3) δ 6.84 (d, 1H), 6.40 (d, 1H), 4.60 (s, 1H), 4.12 (m, 2H), 2.64 (m, 2H), 2.18 (s, 3H), 2.02 (m,2H).

Préparation of methyl 2-(6-methylchroman-5-yloxy)acetate (Compound 4H)

,OH 0'

4H

The mixture of the product from example 4G (3.28 g, 0.020 mol), methylbronioacetate (3.36 g, 0.022 mol), and césium carbonate (9.77 g, 0.030 mol) in100 ml of anhydrous acetonitrile was heated at 60 °C for 2 h. After cooling, the reaction mixture was flltered through Celite®. The filtrate was diluted with 500 ml of diethyl ether, washed with brine, dried over sodium sulfate, and concentrated togive 4H in good purity. 400 MHz ’H NMR (CDCI3) δ 6.90 (d, 1H), 6.58 (d, 1H), 4.41 (s, 2H), 4.12 (m, 2H), 3.S3 (s, 3H), 2.79 (t, 2H), 2.21 (s, 3H), 1.9S (m, 2H). 46 01278 1

Préparation of methyl 2-(8-cyanothio-6-methylchroman-5-yloxy)acetate(Compound 41)

5 41

To a stirred solution of the product from example 4H (4.72 g, 0.02 mol), sodiumthiocyanate (6.48 g, 0.08 mol), and sodium bromide (2.06 g, 0.02 mol) in 15 ml ofmethanol at 0 °C was added a solution of bromine (3.52 g, 0.022 mol) in 15 ml of 10 methanol dropwise over 20 minutes. After the completion of the bromine addition, the reaction mixture was stirred at room température for 1 h, then s concentrated in vacuo to about 5 ml. The resulting residue was taken up in ethylacetate (500 ml), washed with saturated sodium bicarbonate solution, brine, driedover sodium sulfate, concentrated, and purified using normal phase 15 chromatography to afford the title product. 400 MHz *H NMR (CDCI3) δ 7.20 (s,1H), 4.42 (s, 2H), 4.26 (m, 2H), 3.83 (s, 3H), 2.80 (t, 2H), 2.24 (s, 3H), 2.00 (m,2H)..

Préparation of methyl 2-(6-methyl-8-sulfanylchroman-5-yIoxy)acetate 20 (Compound 4J)

4J 47 012781 A solution of the product from example 41 (5.16 g, 17.6 mmol), dithiothreitol(5.43 g, 35.2 mmol), and 0.2 M potassium dihydrogenphosphate (25 ml) in 100 mlof niethanol was refluxed for 1 h under nitrogen, then cooled and concentrated invacuo. The resulting residue was taken up in diethyl ether (200 ml), and washedwith brine, dried over sodium sulfate, concentrated, and purified using normalphase chromatography to afford the title product. 400 MHz *H NMR (CDC13) δ6.93 (s, 1H), 4.41 (s, 2H), 4.22 (m, 2H), 3.82 (s, 3H), 3.64 (s, 1H), 2.79 (t, 2H),2.19 (s, 3H), 1.98 (m,2H).

Préparation of methyl 2-[6-methyl-8-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)chroman-5-yloxyjacetate (Compound 4K)

The product from example 4J (0.80 g, 3.0 mmol) was dissolved in 20 mlanhydrous acetonitrile, then 5-(chloromethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-l,3-thiazole (0.96 g, 3.3 mmol) was added followed bycésium carbonate (1.95 g, 6.0 mmol). The mixture was stirred at roomtempérature for 2 h, then fîltered through Celite®, concentrated, and purified usingnormal phase chromatography to afford the title product. 400 MHz ’H NMR(CDC13) δ 7.98 (d, 2H), 7.64 (d, 2H), 6.98 (s, 1H), 4.40 (s, 2H), 4.25 (m, 2H), 4.18(s, 2H), 3.82 (s, 3H), 2.80 (t, 2H), 2.28 (s, 3H), 2.15 (s, 3H), 1.97 (m, 2H). 48 01278 1

Step 12. Préparation of 2-[6-methyI-8-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methy]thio)chroman-5-yloxy3aceticacid (Compound 4)

The product from example 41K (1.58 g, 2.98 mmol) was dissolved in a mixtureof 20 ml of THF and 4 ml of water, then treated with lithium hydroxidemonohydrate (0.38 g, 9.0 mmol). After stirring at room température for 1 h, thereaction mixture was acidified to pH 3 with 1 N HCl, then extracted with ethylacetate (2 x 40 ml). The combined organics were washed with brine, dried oversodium sulfate, and concentrated. The title product was recrystallized from ethylacetate/hexanes, mp 203.5-205.5 °C; 400 MHz ’H NMR (DMSO-4) δ 12.96(brs, 1H), 8.06 (d, 2H), 7.82 (d, 2H), 6.98 (s, 1H), 4.38 (s, 2H), 4.35 (s, 2H), 4.17(m, 2H), 2.71 (t, 2H), 2.30 (s, 3H), 2.10 (s, 3H), 1.84 (m, 2H). MS m/z 510(M+l). Anal. Calc’d for CwHæNOz&Fa: C, 56.57; H, 4.35; N, 2.75; Found: C,56.18; H, 4.31; N, 2.68.

Example 5

Synthesis of 2-[5-methyl-7-({4-methyl-2-[4-(trifluoromethyl)phenyl](l,3-thiazoI-5-yI)}methylthio)-2,3-dihydrobenzo[bjfuran-4-yIoxy]acetic acid(Compound 5)

5 49 012781

Préparation of 4-(2-bromoethoxy)-3-iodo-l-methyl-2-perhydropyran-2-yloxybenzene (compound 5A)

A mixture of 4D (8.0 g, 0.023 mol), 1,2-dibromoethane (14.54 g, 0.072 mol), andcésium carbonate ( 23.25 g, 0.069 mol) in 30 ml of N,N- dimethylformamide washeated at 80 °C for 2 h, then cooled, and filtered through Celite®. To the filtrate,500 ml of ethyl acetate was added, washed with water, brine, dried overanhydrous sodium sulfate, and concentrated to give 5A in good purity. 400 MHz’H NMR (CDC13) δ 7.08 (d, 1H), 6.54 (d, 1H), 5.07 (m, 1H), 4.30 (t, 2H), 4.12 (m,1H), ?.69 (t, 2H), 3.50 (m, 1H), 2.30 (s, 3H), 2.17-1.52 (m, 6H).

Préparation of 5-methyl-4-perhydropyran-2-yloxy-2,3-dihydrobenzo[b)furan(Compound 5B)

To the product from example 5A (7.27 g, 0.0164 mol) in 100 ml oftetrahydrofuran and 30 ml of hexane, n-buthyllithium (2.5 M in hexane, 7.9 ml,0.0196 mol) was added dropwise over 30 minutes at - 78 °C, and allowed to stir atthe same température for 1 h and at ambient température for 1.5 h, extracted withethyl acetate (3x100 ml), washed with water, brine, dried over anhydrous sodiumsulfate, concentrated and used for the next step without further purification . 400 50 01278î MHz ’H NMR (CDC13) δ 6.90 (d, 1H), 6.45 (d, 1H), 5.10 (m, 1H), 4.55 (t, 2H),4.01 (m, 1H), 3.60 (m, 1H), 3.30 (t, 2H), 2.20 (s, 3H), 1.90-1.80 (m, 3H), 1.70-1.55 (m, 3H).

Préparation of 5-methyl-2,3-dihydrobenzo[b)furan-4-ol (Compound 5C)

A mixture of the product from example SB (3.5 g, 0.014 mol), and pyridinium-p-toluenesulfonate (0.7 g) in methanol (50 ml) was refluxed for 2 h, then cooledand concentrated. The residue was dissolved in ethyl acetate (100 ml), washedwith water, brine, dried over anhydrous sodium sulfate, concentrated, and purifîedusing normal phase chromatography. 400 MHz ’H NMR (CDC13) δ 6.87 (d, 1H),6.34 (d, 1H), 4.61 (t, 2H), 4.55 (s, 1H), 3.15 (t, 2H), 2.20 (s, 3H).

Préparation of (4-hydroxy-5-methyI-(2,3-dihydrobenzo[2,3-b]furan-7-yl))thiocarbonitrile (Compound 5D)

5D

The title compound was prepared in the manner analogous to Example 2A withthe product from example 5C (1.47 g, 0.009S mol), sodium thiocyanate (2.6 g,0.03 mol), sodium bromide (0.99 g, 0.0098 mol), and bromine (1.67 g, 0.0107mol) in 20 ml of anhydrous methanol. 400 MHz ’H NMR (CDCI3) δ 7.08 (s, 1H),4.85 (s, 1H), 4.73 (t, 2H), 3.22 (t, 2H), 2.20 (s, 3H). 51 012781

Préparation of methyl 2-(7-cyanothio-5-methyl-2,3-dihydrobenzo[b]furan-4-yloxy)acetate (Conipound 5E)

The title compound was prepared in the manner anaiogous to Example IB withthe product from example 5D (1.98 g, 0.0095 mol), methylbromoacetate (1.60 g,0.010 mol), and césium carbonate (4.6 g, 0.014 mol) in 50 ml anhydrous 10 acetonitrile. 400 MHz 1H NMR (CDC13) δ 7.12 (s, 1H), 4.70 (t, 2H), 4.62 (s, 2H), 3.81 (s, 3H), 3.35 (t, 2H), 2.22 (s, 3H).

Préparation of methyl 2-(5-methyl-7-suIfanyl-2,3-dihydrobenzo[b]furan-4-yloxy)acetate (Compound 5F) 15

5F 20 The title compound was prepared in the manner anaiogous.to Example 1D withthe product from example 5E (2.6 g; 0.0093 mol), dithiothreitol (1.85 g; 0.0119mol) and 0.2 M potassium dihydrogenphosphate (4.42 ml) in 40 ml of methanol.400 MHz ’H NMR (CDC13) δ 6.87 (s, 1H), 4.69 (s, 2H), 4.52 (t, 2H), 3.70 (s, 3H),3.27 (t, 2H), 2.10 (s, 3H). 52

Préparation of methyl 2-[5-methyî-7-({4-methyl-2-[4-(trifluorometbyl)pbenyl](l,3-thiazol-5-yI)}nietbylthio)-2,3-dihydrobenzo[b]furan-4-yloxy]acetate (Compound 5G)

The title compound was prepared in the manner analogous to Example 1E withthe product from example 5F (600 mg, 2.36 mmol), 5-(chloromethyl)-4-methyl-2-[4-(tr^fluoromethyl)phenyl]-l,3-thiazole (760 mg, 2.59 mmol), and césiumcarbonate (1.54 g, 4.72 mmol) in 25 ml of anhydrous acetonitrile. 400 MHz ’HNMR (CDC13) δ 7.97 (d, 2H), 7.64 (d, 2H), 6.90(s, 1H), 4.60 (t, 2H), 4.55 (s, 2H),4.17 (s, 2H), 3.80 (s, 3H), 3.29 (t, 2H), 2.25 (s, 3H), 2.14 (s, 3H).

Préparation of 2-[5-methyl-7-({4-methyl-2-[4-(trifluoroniethyI)phenyl](l,3-thiazoI-5-yI)}methylthio)-2,3-dihydrobenzo[b]furan-4-yloxy]acetic acid(Compound 5) *

The title compound was prepared in the manner analogous to Example 1 with theproduct from example 5G (1.0 g, 0.0019 mol), and lithium hydroxidemonohydrate (0.25 g, 0.0058 mol) in 15 ml of tetrahydrofuran/water mixture(10:1). mp 157-158 °C. MS mJz 496 (M+l). 400 MHz ]H NMR (DMSO-d6) δ S.05 (d, 2H), 7.82 (d, 2H), 6.90 (s, 1H), 4.65 (s,2H), 4.52 (t, 2H), 4.30 (s, 2H), 3.30 (t, 2H), 2.24 (s, 3H), 2.08 (s, 3H). Anal.Calc’d for CosHooNC^So^: C, 55.75; H, 4.07; N, 2.83; found: C, 55.38; H, 4.18;N, 2.66. 53 01278 1

Example 6

Svnthesis of {5-Methvl-7-r4-methvI-2-f4-trifluorometh vl-phenvl)-thiazol-5- vlmethvlsulfanyll-îndan-4-vloxy)-acetic acid (Compound 6)

Préparation of {5-MethyI-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yimethylsulfanyI]-indan-4-yloxy}-acetic acid methyl ester (Compound 6A)

The title compound was prepared from 5-(chloromethyI)-4-methyl-2-[4-(trifluoromethyl)phenyl]-l ,3-thiazole and (7-mercapto-5-methyl-indan-4-yloxy)-acetic acid methyl ester (prepared in a similar manner as described for Exampîe1D) in a manner analogous to Example 1E. MS m/z 508 (M+l).

Préparation of {5-Methyl-7-[4-methyl-2-(4-triiluoromethyl-phenyI)-thiazol-5-ylmethylsulfanyl]-indan-4-yloxy}-acetic acid (Compound 6) 54 012781

The title compound was prepared fforn the product of Example 6A in the manneranalogous to Example 1. mp 184 °C; 400 MHz ’H NMR (DMSO-J6) δ 12.83 (s,1H), 7.82 (d, 2H, J=8 Hz), 7.76 (d, J=8.4 Hz), 7.00 (s, 1H), 4.43 (s, 2H), 4.29 (s,2H), 2.83 (t, 2H, J=7.2 Hz), 2.65 (t, 2H, J=7.2 Hz), 2.16 (s, 3H), 2.12 (s, 3H), 5 1.86 (m, 2H). MS m/z 494 (M+l).

Example 7

Synthesis of {7-r4-Methyl-2-(4-trifluoromethvl-phenyl)-thiazol-5- ylmethylsulfanyl]-indan-4-vIoxv)-acetic acid (Compound 7) 10

Préparation of Indan-4-ol (compound 7A)

OH

7A A mixture of 4-hydroxy-indan-l-one (5.0 g, 33.7 mmol), sodium .cyanoborohydride (6.4 g, 101.1 mmol), and zinc iodide (32.3 g, 101.1 mmol) in 20 dichloroethane, was heated at reflux for two hours. The reaction mixture was thenfiltered through 50 g SiCb while still warm, eluting further with dichloroethane.The filtrate was collected and concentrated under vacuum. The residue was addedto diethyl ether and the resulting white precipitate was filtered off. The filtratewas collected and concentrated in vacuo to give 4.2 g of the title compound with 25 purity high enough for subséquent use. 400 MHz ’H NMR (DMSO-d6) δ 9.06 (s, 55 012781 1H), 6.86 (t, 1H, 7= 7.8 Hz), 6.59 (d, 1H,7 = 7.8 Hz), 6.48 (d, 1H, 7 = 7.8 Hz),2.75 (t, 2H, 7 = 7.3 Hz), 2.67 (t, 2H, 7 = 7.3 Hz), 1.92 (m, 2H).

Préparation of 7-Thiocyanato-indan-4-ol (compound 7B) 5

OH

SON

7B

The title compound was prepared in the manner analogous to Example 2A using10 the product from Example 7A. MS m/z 192 (M+l).

Préparation of (7-Mercapto-indan-4-yloxy)-acetic acid methyl ester $ (compound 7C) 15

7C 7-Thiocyanato-indan-4-ol (Example 7B) ( 1.47g, 7.7 mmol), césium carbonate20 (3.77g, 11.6 mmol) and methyl bromoacetate (1.24g, 8.08 mmol) were stirred in 20 ml acetonitrile at ambient température for 4 h. The reaction was filtered andconcentrated. The crude product was treated under the conditions of Example 2Dto afford the title product. MS m/z 239 (M+l). 56

Préparation of {7-[4-Methyl-2-(4-trifluoromethyl-phenyI)-thiazoI-5-ylmethylsu!fanyl]-indan-4-yIoxy}-acetic acid methyl ester (Compound 7D)

7D

The title compound was prepared in the manner analogous to Example 1E usingthe products from Example 7C and 5-(chloromethyl)-4-methyl-2-[4-(trifluç>romethyl)phenyl]-l,3-thiazole. MS tn/z 494 (M+l).

Préparation of {7-[4-MethyI-2-(4-trifïuoromethyI-phenyl)-thiazol-5-ylmethyïsulfanyl)-indan-4-yIoxy}-acetic acid (Compound 7)

The title compound was prepared in the manner analogous to Example 1 using theproduct from Example 7D. 400 MHz ’H NMR (DMSO-4) δ 7.99 (d, 2H, 7=8.1Hz), 7.77 (d, 2H, 7=8.3 Hz), 7.09 (d, 1H, 7=8.3 Hz), 6.59 (d, 1H, 7=8.5 Hz), 4:63(s, 2H), 4.22 (s, 2H), 2.75 (m, 4H), 2.09 (s, 3H), 1.89 (m, 2H). MS m/z 480(M+l).

BIOLOGICAL ASSAYS

The compounds of the présent invention hâve demonstrated PPARmodulating activity in the standard assays commonly employed by those skilled inthe art. Accordingly, such compounds and formulations comprising such 57 012781 compounds are useful for treating, preventing or controlling hypercholesterolemiaand hyperlipidemia. A. Selectivity Measurements5 1. Test A. Transient transfections assay using the HepG2 hepatoma cellline.

HepG2 cells were transiently transfected with an expression plasmids 10 encoding hPPARa, hPPARp or mPPARy chimeric receptors and a reportercontaining the yeast upstream activating sequence (UAS) upstream of the viralE1B promoter controlling a luciferase reporter gene. In addition, the plasmidpRSVP-gal was used to control for transfection efficiency. HepG2 cells weregrown in DMEM supplemented with 1O%FBS and ΙμΜ non-essential amino acid. 15 On the first day, cells were split into 100mm dishes at 2.5x106/dish and incubatedovernight at 37C°/5% CO2. On the second day the cells were transientlytransfected with plasmid DNA encoding a chimeric receptor, the luciferasereporter gene; and β-gal. For each 100 mm dish, 15pg of lucifease reporter(PG5Elb) DNA, 15pg of Gal4-PPAR chimeric receptor DNA, and 1.5pg of β-gal 20 plasmid DNA were mixed with 1.4ml of opti-MEM in the tube. 28μ1 of

LipoFectamine-2000 reagént was added to 1.4ml of opti-MEM in the tube, andincubate for 5 min at RT. The diluted Lipofectamine-2000 reagent was combinedwith the DNA mixture, and incubate for 20 min at RT. After fresh medium was .added to each 100mm dish of cells, 2.8ml of Lipofectamine2000-DNA mixture 25 was added dropwise to the 100mm dish containing 14ml of medium, and incubate37°C overnight. On day three cells were trypsinized off thelOO mm dishes and re-plated on 96 well plates. Cells were plated at 2.5xl04cells per well in 150μ1 ofmedia and 50μ1 of compound diluted by media was added. The test compoundadded were in the range from 50μΜ to 50pM. After addition of compounds, the 30 plates were incubated at 37C° for 24 hours. Subsequently cells were washed withonce with 100μ1 of PBS, lysed, and processed for measuring luciferase and β-galactivity using Dual-Light luciferase kit from Tropix ®, according to the 58 012781 manufacturer’s recommendations, on an EG&G Bethold MicroLumat LB96Pluminometer. EC50 values were obtained using the GraphPad Prism™ program.Surprisingly, the compounds of the présent invention exhibit activity for bothPPARa and PPARp. Accordingly, the compounds of the présent invention should 5 find considérable therapeutic applications for hypercholesterolemia and hyperlipidemia. The Hep G2-hBeta EC50 (“ECsoP”) data as well as the Hep G2-hAlpha EC50 (“ECsoOc”) data of the compounds of the invention are shown inTable 1 below. 10 Table 1

Example Hep G2-hp ECsonM Hep G2-haECsonM 1 187 402694 2 52 2966 3 76 3581 < 4 45 1761 5 0.8 52 6 133 191 6 34 2716

FORMULATIONS 15

The compounds of the présent invention can be administered alone or incombination with one or more therapeutic agents. These include, for example,other agents for treating, preventing or controlling dyslipidemia, non-insulindépendent diabètes mellitus, obesity, hyperglycemia, hypercholesteremia, 20 hyperlipidemia, atherosclerosis, hypertriglyceridemia, or hyperinsulinemia.

The compounds are thus well suited to formulation for convenientadministration to mammals for the prévention and treatment of such disorders. 59 012781

The following examples furtber illustrate typical formulations provided bythe invention.

Formulation 1

Ingrédient Amount compound of Formulae I-IH 0.5 to 800 mg sodium benzoate 5 mg isotonie saline 1000 mL 5

The above ingrédients are mixed and dissolved in the saline for IV administrationto a patient.

Formulation 2

Ingrédient Amount compound of Formulae Ι-ΙΠ 0.5 to 800 mg cellulose, microcrystalline 400 mg stearic acid 5 mg Silicon dioxide 10 mg sugar, confectionery 50 mg 10

The ingrédients are blended to uniformity and pressed into a tablet that is wellsuited for oral administration to a patient.

Formulation 3

Ingrédient Amount compound of Formulae I-IH 0.5 to 800 mg starch, dried 250 mg magnésium stéarate 10 mg

The ingrédients are combined and milled to afford material suitable for fillinghard gelatin capsules administered to patient. 15 60 012781

Formulation 4

Ingrédient Amount % wt/(total wt.) compound of Formulae Ι-ΠΙ 1 to50 Polyethylene glycol 1000 32 to 75 Polyethylene glycol 4000 16 to 25

The ingrédients are combined via melting and then poured into molds containing5 2.5 g total weight.

While embodiments of the invention hâve been illustrated and described, itis not intended that these embodiments illustrate and describe ail possible forms ofthe invention. Rather, the words used in the spécification are words of description 10 rather than limitation, and it is understood that various changes may be madewithout departing from the spirit and scope of the invention. 61

Claims

012781 What is claimed is:

1. A compound having formula I:

I or a pharmaceutically acceptable sait thereof,wherein: * T is a saturated or unsaturated, substituted or unsubstituted hydrocarbonchain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein thecarbon atom of position 2 is connected to the carbon atom of position 3 to form afive to eight member ring; W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 wherein Y is CR4R5 or absent when W is O, S, ôr NR3; and Y is O or absent when W is CH2 or CR4R5; R1 and R2 are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)nlOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR6R7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R6 and R7 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; 62 012781 X° and X1 are independently O or S; Ar1 is substituted or unsubstituted aryl or heteroaryl;m is 0 to 5;n is 0 to 5; andp is 0 to 2.

2. The compound of claim 1, wherein: T is -CH2CH2CO-O-, -CH2-CH2-O-CO-, -CH2-CH2-CH2-CH2-, -HC=CH-HC=CH-,-N=CH-HC=CH-, -HC=N-HC=CH-, -HC=CH-N=CH-, -HC=CH-HC=N-, -CH2-CH2-CH2-, -CH2-CH2-O-CH2-, -CH2-HC=CH-CH2-, -ch2-HC=CH-, -CH2CH2-NH-CH2-, -COCH=CH-O-, -O-CH=CH-CO-, -CH=CH-NR4-, -nr4-ch=ch-, -ch=ch-ch2-, -ch2-ch2-nr4-, -nr4-ch2-ch2-, -o-ch2-ch2-, -ch2-ch2-o-, -ch2-ch2.co-, -ch2-co-ch2., -co-ch2-ch2-, -ch2-ch2-ch2-co-, -co-ch2-ch2-ch2-„ -ch2-co-ch2-ch2-, -ch2-ch2-co-ch2-, -ch2-ch2-ch2-nr4-, -nr4-ch2-ch2-ch2-, -o-ch2-ch2-ch2-, -ch2-ch2-ch2-o-, -CO-NR4-CH2-CH2-, NR4CO-CH2-CH2-, -CH2-CH2.NR4-CO-, or-CH2-CH2-CO-NR4-.

3. A compound having Formula Ha, Formula Db, Formula Hc, Formula ïïd,or Formula De:

63 012781

He 10 or a pharmaceutically acceptable sait thereof,wherein: Y1, Y2, Y3 and Y4 are independently a carbon atom or a heteroatomwherein the carbon atom and the heteroatom are bonded to a sufficient number of 15 hydrogen atoms or substituents to complété the valency of each atom with theproviso that Y1, Y2, Y3 and Y4 are not ail heteroatoms and that not more than twoadjacent atoms in Y1, Y2, Y3 and Y4 are heteroatoms and that in Formulae Hb, Ile,and Hd, Y1, Y2, Y3 and Y4 are not ail carbon; W is O, S, CHo, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; 64 012781 Y is absent, O, or CR4R5 wherein Y is CR4R5 or absent when W is O, S, or NR3; and Y is O or absent when W is CH2 or CR4R5; R1 and R2 are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR^7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R6 and R7 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; X° and X1 are independently O or S; Ar1 is substituted or unsubstituted aryl or heteroaryl;m is 0 to 5; * n is 0 to 5; andp is 0 to 2.

4. A compound having Formula Hla, Formula ÏHb, or Formula nie:

65 012781

or a pharmaceutically acceptable sait thereof, wherein: W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 wherein Y is CR4R5 or absent when W is O, S, or NR3; and Y is O or absent when W is CH2 or CR4R5; 1 1 9 R and R" are independently hydrogen, lower alkyl, lower alkoxy,haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl,S(O)paryl, -(CH2)mOR3, -(CH2)mNR6R7, -COR3, -CO2H, -CO2R3, or-NR6R7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R4 and R5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, orjoined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R6 and R7 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO^alkyl, -CO^aryl, -SO2alkyl, -SO2aryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; X° and X1 are independently O or S; Ar' is substituted or unsubstituted aryl or heteroaryl;misOtoS;n is 0 to 5;p is 0 to 2; and 66 012781 Z1, Z2, and Z3 are independently a carbon atom or a heteroatom whereinthe carbon atom and the heteroatom are bonded to a suffîcient number ofhydrogen atoms or substituents to complété the valency of each atom with theproviso that Z], Z2, and Z3 are not ail heteroatoms and that in Fonnulae nia and 5 mb Z1, Z2, and Z3 are not ail carbon atoms.

5. The compound of claim 1,3, or 4, wherein W is O, Y is absent, and n is 1.

6. The compound of claim 1,3, or 4, wherein: 10 R1 and R2 are independently hydrogen, alkyl, or alkoxy.

7. The compound of claim 1,3, or 4, wherein: R1 is hydrogen; and R2 is alkyl or alkoxy. 15

8. The compound of claim 1,3, or 4, wherein: \ 1 R is hydrogen; and R2 is alkoxy. 20

9. A compound selected from {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-5-oxcb5,6,7,8-tetrahydro-naphthalen-1 -yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-8-oxo-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; 25 {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-7- oxo-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-6-oxo-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-30 oxo-4H-chromen-8-yloxy} -acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-4H-chromen-5-yloxy} -acetic acid; 67 012781 {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-chroman-5-yloxy}-acetic acid; {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo-chroman-8-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-quinolin-5-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-isoquinolin-5-yloxy}-acetic acid; {1 -Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-lH-benzoimidazol-4-yloxy}-acetic acid; {3-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-1 H-benzoimidazol-4-yloxy} -acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-lH-indol-4-yloxy}-acetic acid; {l-Methyl-7-[4-methy]-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-lH-indol-4-yloxy J -acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzo[b]thiophen-4-yloxy} -acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzofuran-4-yloxy}-acetic acid; {8-[4-Methyl-2-(4.-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-chroman-5-yIoxyj -acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylrnethylsulfariyî]-5,6,7,8-tetrahydro-naphthalen-l-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-naphthalen-l-yloxy}-acetic acid; 2-[6-methyl-S-( {4-methyl-2-[4-(trifluoromethyl)phenyl]( 1,3-thiazol-5-yl)}methylthio)chroman-5-yloxy]acetic acid; 2-[5-methyl-7-({4-meXhyl-2-[4-(trifluoromethy])phenyl](l,3-thiazol-5-yl)}methylthio)-2,3-dihydrobenzo[b]furan-4-yloxy]acetic acid; {5-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indan-4-yloxy}-acetic acid; 68 01278 1 {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indan-4-yloxy}-acetic acid; andpharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a compound of Claim 1 and oneor more pharmaceutically acceptable carriers, diluents, or excipients.

11. Use of a compound of Claim 1 in the manufacture of a médicament fortreating, preventing or controlling non-insulin dépendent diabètes mellitus in amammal.

12. Use of a compound of Claim 1 in the manufacture of a médicament fortreating, preventing or controlling hyperlipidemia in a mammal.

13? Use of a compound of Claim 1 in the manufacture of a médicament for treating, preventing or controlling hypercholesteremia in a mammal.

14. Use of a compound of Claim 1 in the manufacture of a médicament for treating, preventing or controlling atherosclerosis in a mammal.

15. A method of making the compound of claim 1, the method comprising,'reacting:

with 69 01278 1 Ar wherein X is a halogen; 5 X° and X1 are independently O or S; Ar1 is substituted or unsubstituted aryl or heteroaryl; T is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein thecarbon atom of position 2 is connected to the carbon atom of position 3 to form a 10 five to eight member ring; W is O, S, CH2, CR4R5, NR3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR4R5 wherein Y is CR4R5 or absent when W is O, S, or NR3; and Y is O or absent when W is CH2 or CR4R5; 15 R and R are independently hydrogen, lower alkyl, lower alkoxy, lower thioàlkoxy, -O(CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -OCF3,S(O)nAlkyl, S(O)pAryl, -(CH2)mOR3, -(CH2)raNR6R7, COR3, -CO2H, -CO2R3, or-NR6R7; R3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; 20 R4 and R5 are independently hydrogen, alkyl, âlkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R6 and R7 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyL -CO2aryI, -SO2alkyl, -SO2aryl, or joined togetherto form a 4 to 7 member ring having 1 to 3 heteroatoms; 25 mis0to5; n is 0 to 5; andp is 0 to 2. 70